How big is the Chinese market opportunity for Exdensur?

According to GSK, China has approximately 46 million asthma patients, with severe cases representing around 6% — roughly 2 million high-risk patients eligible for biologic therapy.

What makes Exdensur different from competing asthma biologics in China?

GSK describes Exdensur as the first ultra-long-acting biologic approved in China for severe asthma, requiring only two doses per year versus more frequent dosing schedules for rival biologics.

Why is GSK's stock down despite the China approval?

The approval was announced approximately 8 days before current trading, suggesting the market has partially priced in the news. China pricing negotiations and delayed revenue contribution may also be weighing on sentiment.

What other markets has GSK received Exdensur approval in?

Prior to China, GSK secured regulatory approvals for Exdensur in the United States, European Union, Japan, and the United Kingdom.

त्वरित लिंक

GSK Wins China NMPA Approval for Exdensur (Depemokimab) in Severe Asthma — First Ultra-Long-Acting Biologic in Market

प्रकाशित: 2026-04-08 08:24:59 UTC

देखें GSK पृष्ठ मार्केट आउटलुक देखें

डेटा स्नैपशॉट

Price

$55.80

24h Low

$55.11

24h High

$55.95

GSK Price

$55.80

24h Change

-1.07%

24h Change (%)

-1.07%

मुख्य निष्कर्ष

•China NMPA approved Exdensur (depemokimab) for severe eosinophilic asthma on March 30–31, 2026 — NOT nasal polyps, which remains under review.
•GSK positions Exdensur as 'the first and only ultra-long-acting biologic in China' for this indication, with a differentiated twice-yearly dosing advantage.
•SWIFT-1 and SWIFT-2 trials showed 58% and 48% annualized exacerbation rate reductions — strong clinical backing for commercial uptake.
•GSK is trading at $55.80 (-1.07%), suggesting partial pricing-in; watch for earnings guidance updates as a re-rating catalyst.
•A pending CRSwNP approval in China represents additional upside optionality beyond the current asthma indication.

According to GSK's official press release and SEC filings, China's National Medical Products Administration (NMPA) approved Exdensur (depemokimab) for the treatment of severe eosinophilic asthma on Ma

Event Analysis

According to GSK's official press release and SEC filings, China's National Medical Products Administration (NMPA) approved Exdensur (depemokimab) for the treatment of severe eosinophilic asthma on March 30–31, 2026. Important clarification: the approval covers severe asthma, not nasal polyps — a separate CRSwNP (chronic rhinosinusitis with nasal polyps) indication remains under review in China. This distinction matters for investors assessing the revenue runway.

The commercial significance is substantial. GSK describes Exdensur as "the first and only ultra-long-acting biologic in China" for this indication, with a differentiated twice-yearly dosing schedule that enhances patient adherence versus more frequent competitors. China's severe asthma population is estimated at approximately 2 million high-risk patients — roughly 6% of the country's 46 million asthma sufferers, per GSK data. Pivotal trials SWIFT-1 (n=382) and SWIFT-2 (n=380) demonstrated 58% and 48% annualized exacerbation rate reductions respectively, with a safety profile comparable to placebo.

Strategically, this approval completes a major-market sweep: GSK had previously secured clearances in the US, EU, Japan, and UK. Entering China last — the world's most populous market — signals regulatory execution maturity and strengthens Exdensur's global commercial platform. The pending CRSwNP approval represents a meaningful upside optionality on top of the asthma indication. For the broader 2026 Stocks Market Outlook, China-facing pharma approvals remain a key catalyst theme as multinationals compete for Asia-Pacific biologics market share.

What This Means for Traders

According to live market data, GSK is currently trading at $55.80, down 1.07% on the day with a 24h range of $55.11–$55.95. The muted intraday price action — despite a meaningful regulatory win — suggests the market may have partially priced in the approval given its announcement 8 days prior. Traders should assess whether a full re-rating has occurred or whether continued momentum is possible, particularly if GSK updates earnings guidance to incorporate China revenue projections.

The sentiment backdrop is modestly bullish for GSK CFD positions. The FTSE 100 Index could see marginal positive spillover, as GSK remains one of its larger healthcare constituents. The STOXX Europe 600 Index may see a similar, smaller effect. Key risk: China's typical pricing pressure on biologics through national reimbursement negotiations could compress margins. Monitor any GSK earnings guidance revision or China market penetration updates as primary confirmation signals. Volatility is expected to remain contained unless the CRSwNP indication receives approval soon, which would represent a fresh catalyst.

The US Dollar / Chinese Yuan pair has no direct link to this event, and cross-market effects on commodities and crypto are negligible.

Trade GSK plc on CoinUnited.io

Trade GSK with up to 800xx leverage → | Create Free Account

अक्सर पूछे जाने वाले प्रश्न

China's NMPA approved Exdensur (depemokimab) specifically for severe eosinophilic asthma. The nasal polyps (CRSwNP) indication is still under regulatory review in China.